Sunday, September 26, 2021 7:42:40 AM
I agree with all those facts…..
The publicly filed accounts of Advent also provide factual financials which include The share capital, trade debtors, creditors and cash balances as at the end of 2019. Anders has already posted them for all to see.
In all of this debate re Advent / conflicts of interest it could all be easily answered and put to bed if Mgt went on to PR/demonstrate beyond doubt that no NWBO shareholders have suffered any financial losses, funded the risk but lost out on the upside either in the past, now or in the future as Advent develops post certification, TLD & approval. This should be done by a PR and not via any individual shareholder that has the ear of Management.
I cannot see why this subject should be covered by a “quiet period” as it does not mention anything regarding the trial results. Good communications and strong corporate governance only adds to the reasons why new investors will jump aboard on TLD…
The publicly filed accounts of Advent also provide factual financials which include The share capital, trade debtors, creditors and cash balances as at the end of 2019. Anders has already posted them for all to see.
In all of this debate re Advent / conflicts of interest it could all be easily answered and put to bed if Mgt went on to PR/demonstrate beyond doubt that no NWBO shareholders have suffered any financial losses, funded the risk but lost out on the upside either in the past, now or in the future as Advent develops post certification, TLD & approval. This should be done by a PR and not via any individual shareholder that has the ear of Management.
I cannot see why this subject should be covered by a “quiet period” as it does not mention anything regarding the trial results. Good communications and strong corporate governance only adds to the reasons why new investors will jump aboard on TLD…
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
